The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF)

Nakamura, Masataka; Oda, Shigeto; Sadahiro, Tomohoto; Hirayama, Yoh; Tateishi, Yohei; Abe, Ryuzo; Hirasawa, Hiroyuki

doi:10.1016/j.transci.2008.11.004

Cited by 33 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, she developed laboratory abnormalities consistent with TLS. 10 In conclusion, our case describes tumor lysis syndrome as another complication that clinicians should recognize following ruxolitinib discontinuation in addition to the already well-described ruxolitinib withdrawal syndrome in patients with MF. 9 Our case is the first to report TLS after ruxolitinib discontinuation.…”

Section: Diagnosis In Oncologymentioning

confidence: 54%

Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis

Dai

Friedman

Barta

2013

JCO

View full text Add to dashboard Cite

A 70-year-old woman with a history of JAK2 V617F mutationpositive post-polycythemia vera (PV) myelofibrosis (MF) presented to the emergency department 4 weeks after discontinuing ruxolitinib with abdominal pain and massive splenomegaly, acute renal failure, hyperkalemia, hyperuricemia, hypocalcemia, and hyperphosphatemia.She was diagnosed with PV 10 years before admission. At that time she had a hemoglobin (Hgb) of 18 g/dL, an elevated red cell mass (51.3 mL/kg; reference range [RR], 24-30 mL/kg), and a hypercellular bone marrow (98%) with clustered megakaryocytes without fibrosis. Cytogenetic analysis showed 70% of cells with trisomy 9 and deletion 20q. She carried the JAK2 V617F mutation, and reverse transcriptase polymer chain reaction was negative for the BCR/ABL transcript. Her WBC count was 25.5 ϫ 10 3

show abstract

Section: Diagnosis In Oncologymentioning

confidence: 54%

Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis

Dai

Friedman

Barta

2013

JCO

View full text Add to dashboard Cite

show abstract

“…Further, CVVH can act as a substitute for renal functions and correct electrolyte disturbances, thus helping the patient to survive high-risk period during TLS. Nakamura et al [14] also found that the level of the intra-corporeal cell factors in the patient with TLS (α-TNF, IL-6, IL-8 and IL-10) was apparently higher than that in the healthy population, suggesting t]hat cell factors may participate in the occurrence and progression of TLS. After CVVH, all of the cell factors were markedly decreased.…”

Section: Discussionmentioning

confidence: 97%

Complicated tumor lysis syndrome after CVVH treatment in a renal transplantation patient: One case report and literature review

Liu

Yang

et al. 2009

Clin. Oncol. Cancer Res.

View full text Add to dashboard Cite

“…Another major cause of serious offtarget AE is tumor lysis syndrome (TLS) associated with the rapid and massive destruction of tumor cells, which makes high treatment efficacy a double-edged sword. The pathophysiological features of TLS considerably overlap those of a cytokine storm [59]. A fatal complication of treatment with CD19-CAR-T cells has been reported in a patient who manifested increased serum levels of phosphorus, potassium and uric acid, being compatible with TLS.…”

Section: Adverse Effects Impeding the Efficacy Of Treatment With Genementioning

confidence: 99%

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors

Fujiwara

2013

Int J Hematol

View full text Add to dashboard Cite

The functional properties of the adoptive immune response mediated by effector T lymphocytes are decisively regulated by their T-cell receptors (TCRs). Transfer of genes encoding target antigen-specific receptors enables polyclonal T cells to redirect toward cancer cells and virally infected cells expressing those defined antigens. Using this technology, a large population of redirected T cells displaying uniform therapeutic properties has been produced, powerfully advancing their clinical application as "cellular drugs" for adoptive immunotherapy against cancer. Clinically, anticancer adoptive immunotherapy using these genetically engineered T cells has an impressive and proven track record. Notable examples include the dramatic benefit of chimeric antigen receptor gene-modified T cells redirected towards B-cell lineage antigen CD19 in patients with chronic lymphocytic leukemia, and the impressive outcomes in the use of TCR gene-modified T cells redirected towards NY-ESO-1, a representative cancer-testis antigen, in patients with advanced melanoma and synovial cell sarcoma. In this review, we briefly overview the current status of this treatment option in the context of hematological malignancy, and discuss a number of challenges that still pose an obstacle to the full effectiveness of this strategy.

show abstract

The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF)

Cited by 33 publications

References 21 publications

Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis

Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis

Complicated tumor lysis syndrome after CVVH treatment in a renal transplantation patient: One case report and literature review

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors

Contact Info

Product

Resources

About